argus

Mankind Pharma Limited

NSE: MANKINDINE634S0102897,467 Cr

Timeline

Time (IST)TypeMEventSrc
02 Jun, 05:45 pmMankind Pharma Limited has informed the Exchange about Acquisitionnse
02 Jun, 05:38 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Acquisitionbse
26 May, 05:01 pmMankind Pharma Limited has informed the Exchange about Transcriptnse
26 May, 05:01 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
20 May, 04:06 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
20 May, 04:02 pmMankind Pharma Limited has informed the Exchange about Link of Recordingnse
19 May, 08:07 pmMankind Pharma Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Press Release Q4FY26 & FY26".nse
19 May, 08:06 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
19 May, 08:00 pmMankind Pharma Limited has informed the Exchange about Investor Presentationnse
19 May, 08:00 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
19 May, 07:47 pmMankind Pharma Limited has informed the Exchange about Resignation of Director/KMP/SMPnse
19 May, 07:31 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Change in Managementbse
19 May, 07:27 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Acquisitionbse
19 May, 07:24 pmMankind Pharma Ltd - 543904 - Board Meeting Outcome for Please Find Attached The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026bse
19 May, 07:21 pmMankind Pharma Limited has informed the Exchange regarding Cessation of Mr Pramod Gokhale as Other of the company w.e.f. May 31, 2026.nse
19 May, 07:21 pmMankind Pharma Ltd - 543904 - Financial Results For The Quarter And Financial Year Ended March 31, 2026bse
19 May, 07:19 pmMankind Pharma Limited has informed the Exchange regarding Appointment of Ms M. K. Kulshrestha & Associates, Cost Accountants as Other of the company w.e.f. May 19, 2026.nse
19 May, 07:17 pmMankind Pharma Limited has informed the Exchange regarding Appointment of Mr Satish Kumar Sharma as Executive Director of the company w.e.f. September 23, 2026.nse
19 May, 07:14 pmMankind Pharma Limited has informed the Exchange about Acquisitionnse
19 May, 07:13 pmMankind Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.nse
12 May, 06:24 pmMankind Pharma Limited has informed the Exchange about Credit Ratingnse
12 May, 06:18 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
07 May, 06:48 pmMankind Pharma Ltd - 543904 - Board Meeting Intimation for Inter Alia, Consider And Approve The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31, 2026 And Realignment Of Security Cover Provided In Respect Of Existing Ncds.bse
06 May, 06:02 pmMankind Pharma Ltd - 543904 - Compliances-Reg.24(A)-Annual Secretarial Compliancebse
22 Apr, 08:46 pmMankind Pharma Limited has informed the Exchange about Credit Rating- Newnse
22 Apr, 08:18 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
16 Apr, 04:47 pmMankind Pharma Ltd - 543904 - Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCDbse
13 Apr, 03:29 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Restructuringbse
13 Apr, 03:27 pmMankind Pharma Limited has informed the Exchange about Sale or disposalnse
13 Apr, 03:23 pmMankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 13, 2026.nse
18 Mar, 10:02 amMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Mar, 10:00 amMankind Pharma Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Mankind Pharma acquires Rivotril brand for India, reinforcing focus on chronic CNS therapies".nse
27 Feb, 01:28 pmMankind Pharma Ltd - 543904 - Clarification Submitted By Mankind Pharma Limitedbse
27 Feb, 11:58 amMankind Pharma Ltd - 543904 - Clarification sought from Mankind Pharma Ltdbse
26 Feb, 06:26 pmMankind Pharma Limited has informed the Exchange about General Updatesnse
26 Feb, 06:24 pmMankind Pharma Ltd - 543904 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015bse
24 Feb, 06:21 pmMankind Pharma Limited has informed the Exchange about Credit Rating- Revisionnse
24 Feb, 06:20 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Credit Ratingbse
16 Feb, 06:50 pmMankind Pharma Limited has informed the Exchange about General Updatesnse
16 Feb, 06:49 pmMankind Pharma Ltd - 543904 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015bse
09 Feb, 03:03 pmMankind Pharma Limited has informed the Exchange about General Updatesnse
09 Feb, 03:01 pmMankind Pharma Ltd - 543904 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015bse
09 Feb, 01:41 pmMankind Pharma Limited has informed the Exchange about Transcriptnse
09 Feb, 01:37 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
03 Feb, 10:01 pmMankind Pharma Limited has informed the Exchange about Link of Recordingnse
03 Feb, 09:53 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
03 Feb, 04:25 pmMankind Pharma Ltd - 543904 - Compliances-Reg. 54 - Asset Cover detailsbse
03 Feb, 04:24 pmMankind Pharma Limited has informed the Exchange regarding Board meeting held on February 03, 2026.nse
03 Feb, 04:22 pmMankind Pharma Limited has informed the Exchange about Investor Presentationnse
03 Feb, 04:21 pmMankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentationbse